Cwm LLC Grows Stock Position in Corcept Therapeutics Incorporated $CORT

Cwm LLC raised its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 135.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 28,297 shares of the biotechnology company’s stock after purchasing an additional 16,304 shares during the quarter. Cwm LLC’s holdings in Corcept Therapeutics were worth $2,352,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CORT. Huntington National Bank boosted its position in shares of Corcept Therapeutics by 54.0% during the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock worth $35,000 after buying an additional 168 shares during the period. Focus Partners Wealth boosted its holdings in Corcept Therapeutics by 0.5% during the 1st quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company’s stock valued at $3,797,000 after acquiring an additional 170 shares during the period. Nisa Investment Advisors LLC grew its position in Corcept Therapeutics by 1.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 180 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Corcept Therapeutics by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 44,100 shares of the biotechnology company’s stock worth $3,237,000 after purchasing an additional 200 shares during the period. Finally, Intellectus Partners LLC lifted its position in shares of Corcept Therapeutics by 0.5% during the second quarter. Intellectus Partners LLC now owns 42,251 shares of the biotechnology company’s stock worth $3,101,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Stock Up 9.8%

Shares of NASDAQ CORT opened at $38.20 on Friday. The business has a 50-day moving average of $76.45 and a two-hundred day moving average of $74.78. The company has a market capitalization of $4.02 billion, a price-to-earnings ratio of 43.41 and a beta of 0.23. Corcept Therapeutics Incorporated has a 1 year low of $32.99 and a 1 year high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). The business had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.Corcept Therapeutics’s revenue was up 13.8% on a year-over-year basis. During the same period last year, the business posted $0.41 EPS. On average, analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CORT shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 15th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a research note on Wednesday. Finally, Canaccord Genuity Group reduced their price target on Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $80.83.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating, signaling some sell‑side conviction that there is still meaningful upside from current levels if the company resolves regulatory issues or demonstrates efficacy in follow‑up data. Benzinga
• Neutral Sentiment: Options implied volatility has surged, reflecting elevated uncertainty and trader interest; that can amplify price moves (both rebounds and further declines) and is likely contributing to today’s bounce as short squeezes / gamma flows unwind. Implied Volatility Surging for Corcept Stock Options
• Neutral Sentiment: Unusually large options trading was reported around CORT, consistent with the volatility spike; that activity can produce sharp intraday rallies even when fundamentals remain unchanged. Monitor open interest and large‑block trades for clues to whether the move is technical/speculative versus a change in fundamentals. Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
• Negative Sentiment: The FDA issued a Complete Response Letter for relacorilant, saying the agency needs additional evidence of effectiveness for treating hypercortisolism (Cushing’s). That CRL drove the prior ~50%+ collapse in the share price and is the core fundamental headwind — approval now requires more data or discussions with the FDA that could delay or derail the drug’s U.S. launch. Corcept Receives Complete Response Letter for Relacorilant
• Negative Sentiment: Multiple outlets summarize the practical impact: analysts and investors marked down valuations and the stock hit new lows after the FDA decision — this is an ongoing risk to revenue/cash‑flow forecasts if relacorilant was a key growth driver. Corcept Tanks on FDA’s CRL to Relacorilant NDA in Hypercortisolism
• Negative Sentiment: Kaplan Fox has alerted investors to a possible securities‑law investigation into Corcept, which can prolong downside pressure and raise potential legal/settlement expenses. This increases headline risk even if operational issues are later resolved. Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations

Insider Activity at Corcept Therapeutics

In related news, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.53, for a total value of $397,650.00. Following the completion of the sale, the insider directly owned 10,277 shares of the company’s stock, valued at $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $89.94, for a total value of $1,798,800.00. Following the transaction, the insider directly owned 5,287 shares in the company, valued at approximately $475,512.78. The trade was a 79.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 196,700 shares of company stock valued at $15,474,198. Corporate insiders own 20.80% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.